45
2
abonnés
GeneCreek's mission is to discover microbiota improving healthcare and well-being.
Many human and animal health scientists will nowadays agree that the microbiome offers as yet mostly unexplored opportunities for care, not only for acute and local diseases affecting the body sites harbouring microbes, but also for chronic and systemic disease.
GeneCreek pursues "bugs as drugs" development with a portfolio of QPS/GRAS species and associated disease-specific benefits addressing immunologic, infectious and metabolic diseases.
Regarding "drugs for bugs" development, GeneCreek has built a multi-cohort dataset of several thousands of clinically relevant microbiome samples in which bacterial antagonism mediators targeting important multi-drug resistant pathogens are being mined.
GeneCreek is filing international patent applications for combinations of bacterial species (composition of matter) and their individual effects in particular diseases, sustaining the structure claims that can be made for probiotics and providing elements for eventual medicinal product registration. Partnerships with the probiotics- and pharmaceutical industry are bein established to pursue these opportunities.
Publié il y a 7 ans
GeneCreek SAS has obtained the Fench national tax refund agreement "Crédit Impôt Recherche" (CIR). This agreement secures our fiscal young innovative company (Jeune Entreprse Innovante - JEI) and also allows legal entities based in France to benefit from tax refunds when subcontracting R&D to GeneCreek. The agreement is valid for 3 years, 2016-2018.
Publié il y a 7 ans
GeneCreek launched its 16S rRNA Profiling offer at the 2nd Translational Microbiome conference in Boston last week.
Microbiome at the bench - therapeutic opportunities in the microbiome
Il n'y a pas encore d'organisations dans le réseau.
